drugset / Trial / NCT00708656
The Colitis Once Daily Asacol Study
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.
Timeline
- Start
- 2006-10
- Primary completion
- 2010-07
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesalamine | Small molecule | 800 mg | Oral |
| Subject | Mesalamine | Small molecule | 2.4 g | Oral |